Antithrombotic therapy in valvular heart disease

Clinics in Geriatric Medicine

Volumn 17, Issue 1, 2001, Pages 163-172

  Stein, Paul D ^a  

^a ST JOSEPH MERCY OAKLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

AGED; AGING; ANTICOAGULATION; BIOPROSTHESIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG INDICATION; DRUG SAFETY; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; META ANALYSIS; PRACTICE GUIDELINE; REVIEW; VALVULAR HEART DISEASE;

EID: 0035110030     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(05)70112-9     Document Type: Article

References (60)

1. AREVA: Multicenter randomized comparison of low-dose versus standard dose anticoagulation in patients with mechanical prosthetic heart valves
2. Long-term results with the Medtronic-Hall valvular prosthesis
3. Atrial fibrillation and stroke. Three studies, three remaining questions
4. Experience with moderate intensity anticoagulation and aspirin after mechanical valve replacement: A retrospective, non-randomized study
5. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves
6. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant
7. Anticoagulant related complications in elderly patients with St: Jude mechanical valve prostheses
8. Long-term results of the Carpentier-Edwards pericardial aortic valve: A 12-year follow-up
9. A 51/2 year experience with the St. Jude Medical cardiac valve prosthesis: Early and late results of 737 valve replacements in 671 patients
10. Mitral annular calcification and the risk of stroke in an elderly cohort
11. Management of thrombo-embolism after aortic valve replacement with the Björk-Shiley tilting disc valve: Medicamental prevention with Dicumarol in comparison with Dipyridamole-acetylsalicylic acid. Surgical treatment of prosthetic thrombosis
12. Pericarbon pericardial valve prosthesis: Midterm results of the aortic valve replacement
13. Optimal oral anticoagulant therapy in patients with mechanical heart valves
14. Patients with mitral stenosis and systemic emboli
15. Twenty-year follow-up of the Hancock modified orifice porcine aortic valve
16. Systemic embolism in mitral valve disease
17. The Hancock II bioprosthesis at 12 years
18. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia
19. Risk factors for complications of chronic anticoagulation: A multicenter study
20. Mitral valve replacement: Randomized trial of St. Jude and Medtronic Hall prostheses
21. Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac surgery
22. Determinants of 15-year outcome with 1, 119 standard Carpentier-Edwards porcine valves
23. Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: A survey of five years' experience
24. The risk of thromboembolism and hemorrhage following mitral valve replacement
25. Aging and the anticoagulant response to warfarin therapy
26. Age-related risks of long-term oral anticoagulant therapy
27. Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve the aortic position
28. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
29. Intracardiac thrombosis: Patient-related and device-related factors
30. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St. Jude Medical Prostheses
31. Risk factors for intracranial hemorrhage in outpatients taking warfarin
32. Carpentier-Edwards standard porcine bioprosthesis: A 21-year experience
33. Medtronic intact porcine bioprosthesis: 10 years' experience
34. Carpentier-Edwards supra-annular porcine bioprosthesis evaluation over 15 years
35. A 20-year experience with the Hancock porcine xenograft in the elderly
36. Aortic valve replacement with the St. Jude Medical prosthesis and fixed dose anticoagulation
37. Long term follow-up of St. Jude Medical prosthesis in a young rheumatic population using low-level warfarin anticoagulation: An analysis of the temporal distribution of causes of death
38. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
39. Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1010 treatment years in 551 outpatients
40. Non-bacterial thrombotic endocarditis: A review
41. Thromboembolic and other events following valve replacement in a pediatric population treated with antiplatelet agents
42. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: A randomized trial in patients with mechanical prosthetic heart valves
43. Silent infarcts in patients with ischemic stroke are related to age and size of the left atrium
44. Aging and warfarin therapy
45. Twelve-year experience with the 19 mm Carpentier-Edwards pericardial aortic valve
46. Carpentier-Edwards pericardial bioprosthesis in aortic or mitral position: A 12-year experience
47. 15-Year experience with the Carpentier-Edwards pericardial bioprosthesis
48. Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves: A meta-analysis of the randomized trials
49. Antiplatelet drugs and the incidence of thromboembolic complications of the St. Jude medical aortic prosthesis in patients with rheumatic heart disease
50. Antithrombotic therapy in valvular heart disease
51. The choice of anticoagulation in pediatric patients with the St. Jude Medical valve prostheses
52. Use of enoxaparin for the chronically anticoagulated patient before and after procedures
53. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves
54. Continuing disease process of calcific aortic stenosis
55. Bleeding during antithrombotic therapy in patients with atrial fibrillation
56. Comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement
57. Eight years' experience with the Medtronic-Hall valve prosthesis
58. Bleeding complications in oral anticoagulant therapy
59. Considerations in selection and management of patients undergoing valve replacement with glutaraldehyde-fixed procine bioprostheses
60. Low-dose anticoagulant management of patients with St. Jude Medical mechanical valve prostheses